Kornimate/medical-research-clean huggingface dataset:
tranexamic acid for the treatment of gastrointestinal bleeding

Conditions: Gastrointestinal Bleeding

Summary: studies showed that in cases of gastrointestinal bleeding, injection tranexamic acid decreasing the risk of death and the need of surgical intervention. however, the quality of most clinical trials were not good and the results were not significant. injection tranexamic acid does not become one of the treatment option in the international guidelines nor in national consensus, so the effectiveness and the safety of its use in the treatment of gastrointestinal bleeding remains unclear and not routinely used. in indonesia, injection tranexamic acid in gastrointestinal bleeding is limitedly used and recorded. therefore, a clinical trial study of injection tranexamic acid is required to assess the effectiveness and the safety in the treatment of gastrointestinal bleeding.

this study is a randomized double-blind controlled trial study. interventions were given in the form of tranexamic acid injection compared to placebo in patients with acute upper and lower gastrointestinal bleeding. tranexamic acid were administered intravenously 1 gram loading dose, followed by 3 grams maintenance dose in infusion for 24 hours. other routine and standardized drugs for gastrointestinal bleeding will still be given. statistical analysis will use: chi square test or kolmogorov-smirnov with alternative fisher test for categorical dependent-variable; independent t-test with alternative mann-whitney test for two-group numerical dependent-variable; and one-way anova with alternative kruskal-wallis for more than two-groups numerical dependent-variable.

Eligibility criteria:
inclusion criteria: * adults * patients with acute lower and upper gastrointestinal bleeding (assessed clinically) * patients agreed to participate in the study and signed the informed consent exclusion criteria: * allergy with tranexamic acid * patients considered by the clinician can not be randomized to participate in the study * patients with chronic kidney disease stage iii - v

Keywords: gastrointestinal bleeding tranexamic acid clinical trial
observational database on deep brain stimulation in tourette syndrome

Conditions: Tourette Syndrome

Summary: within an ongoing deep brain stimulation (dbs) program for tourette syndrome (ts) at the department of neurology, pitié-salpêtrière hospital, paris/france, the investigator team plans to evaluate patients pre-operatively and then at one year intervals post-operatively until the 5-year mark has been achieved. the investigator team will investigate tic severity, psychiatric co-morbidities, quality of life, and neuropsychological measures.

since the completion of the stic trial in 2017, the french team continues to offer dbs of the globus pallidus internus (gpi) to selected, treatment-refractory patients with ts. on average, three to four patients undergo surgery every year. even though a first follow-up of the stic cohort up to four years post-op indicates ongoing improvement of tic severity, many questions remains regarding the efficacy of gpi dbs in ts. these questions include frequent comorbidities of ts, quality of life, evolution of medication and stimulation parameters, as well as neuropsychological functioning. therefore, the investigator proposes to evaluate all patients undergoing gpi dbs for ts to be evaluated comprehensively pre-operatively and once yearly after surgery until reaching the 5-year mark. the investigator team hopes these data may help to plan for future international multicenter trials, and provide indications on prognostic factors concerning response to gpi dbs in ts.

Eligibility criteria:
inclusion criteria: * tourette syndrome severe and drug-resistant eligible for bilateral deep brain stimulation * person who voluntarily and knowledgeably agreed to participate in the study exclusion criteria: * non affiliation to a french social security system (recipient or assign) excluding ame

Keywords: bilateral deep brain stimulation tourette syndrome,
the phonophoresis of lidocaine gel and its effect on sensory blockage

Conditions: Pain; Impairment, Light Touch Sensation

Summary: the optimisation of drug absorption through skin is of great value in modern therapy.phonophoresis is the use of therapeutic ultrasound to increase percutaneous drug absorption. however,few studies have compared pulsed and continuous modes of therapeutic ultrasound.this study compared these two modes by investigating the effect of lidocaine phonophoresis on sensory blockade. ninety-three healthy volunteers, assigned at random to one of three ultrasound groups:pulsed(ultrasound+lidocaine),continuous(ultrasound+lidocaine)and control(sham ultrasound+lidocaine). lidocaine was administered transdermally using a transducer.two point discrimination, touch and maximum pain thresholds were assessed before and after the intervention in each group. pulsed ultrasound with topical lidocaine gel induced greater anaesthetic effect compared with continuous ultrasound with topical lidocaine gel and lidocaine application alone. the mechanical properties of pulsed ultrasound appear to be responsible for greater drug penetration.

lidocaine is a common local anaesthetic drug that is used topically to relieve pain,itching and burning, and also for minor surgery.however,its application via this conductive method,has been confined to surface anaesthesia because it seems that it is not possible to have a deep transmission with local drug massage, without injection or systematic administration.on the other hand,the injection of lidocaine can lead to tissue injury and pain,and its use is not advised in children. phonophoresis is one of the common procedures for reducing these problems. therefore, the main aim of this study was to compare the two modes of therapeutic ultrasound by assessing the effect of lidocaine gel phonophoresis on percutaneous absorption and sensory blockade.

Eligibility criteria:
inclusion criteria: * men and women aged 18 to 25 years exclusion criteria: * individuals who had a disease that could affect the experiment, such as systemic disease,impairment of the sensory system(e.g.neuropathy,diabetes),cardiovascular disorders(e.g. increased blood pressure),pain due to an injury to the upper extremity,tumours,malignant and precancerous tissue,acute infection and broken skin in the area; and individuals taking medication to relieve disease symptoms were excluded
comparison of methotrexate (mtx) and the vibex™ mtx device

Conditions: Rheumatoid Arthritis (RA)

Summary: relative bioavailability comparison study

a phase 2, open-label, randomized, 3-way crossover study to compare the relative bioavailability of oral methotrexate and the vibex™ mtx device in adult subjects with rheumatoid arthritis

Eligibility criteria:
inclusion criteria: * male or female patients ≥18 years of age, diagnosed with rheumatoid arthritis exclusion criteria: * pregnant females * any other clinically significant disease or disorder which, in the opinion of the investigator might put the subject at risk
study evaluating mylotarg (gemtuzumab ozogamicin) in usual care

Conditions: Acute Myeloid Leukemia

Summary: this study is designed to assess the safety of mylotarg therapy in routine practice.


Eligibility criteria:
inclusion criteria: * treated by mylotarg * provide icf

Keywords: leukemia
effect of trans-nasal afferent loop decompression on post-pancreaticoduodenectomy pancreatic fistula

Conditions: Pancreatic Fistula; Pancreaticoduodenectomy; Complication of Surgical Procedure

Summary: postoperative pancreatic fistula (popf) is a major complication and an important cause of mortality after pancreaticoduodenectomy (pd). trans-nasal afferent loop decompression technique (tnald) may reduce the rate of popf based on our previous retrospective study. the aim of this open-label randomized controlled trial is to determine whether tnald is a protective factor against the development of popf after pd.

in our previous retrospective study, decompression of the afferent jejunal and pancreatic and biliary anastomoses with a special nasogastric tube and postoperative continuous closed negative pressure suction was shown to be associated with a reduction in overall popf rate from 39% to 27% after pd. however, tnald has the potential theoretical risk of increased morbidity including pulmonary complications and delayed gastric emptying. the objective of this prospective randomized study is to evaluate the impact of trans-nasal afferent loop decompression on the incidence of complications after pd, especially popf rate according to international study group of pancreatic surgery (isgps) 2016 updates. we hypothesize that the tnald may prevent the development of popf after pd. this study randomizes patients to tnald versus no tnald group. subgroup analysis of the outcomes in different popf risk groups is also planned.

Eligibility criteria:
inclusion criteria: * patient scheduled for elective open pancreaticoduodenectomy with child reconstruction * age \> 18 years and ≤ 85 years * full agreement to participate and written informed consent is given exclusion criteria: * emergent pancreaticoduodenectomy * laparoscopic pancreaticoduodenectomy or robotic pancreaticoduodenectomy, including transition to open approach * participant in other trials of pancreaticoduodenectomy with interfering interventions and/or endpoints * patient with severe co-morbidity(s) before surgery, including severe insufficiency in kidney, heart and/or liver, etc. * patient had medication history of corticosteroids over 3 days during last 30 days before surgery * no need for pancreaticojejunostomy during pancreaticoduodenectomy (i.e. past left pancreatectomy, pancreaticogastrostomy, etc.), or pancreatic anastomosis cannot be reconstructed for any reason * external stenting is used during the surgery for any reason * nasogastric tube is inserted and kept for postoperative gastric decompression * in any situation that the placement of afferent loop decompression tube is medically inappropriate or not infeasible
xerecept® (hcrf) for primary glioma patients requiring dexamethasone to treat peritumoral brain edema

Conditions: Brain Edema; Brain Tumor

Summary: the purpose of this study is to examine the safety and efficacy of xerecept (human corticotropin-releasing factor, or hcrf) compared to dexamethasone in patients with primary malignant glioma who require increased dexamethasone doses to control symptom of peritumoral brain edema.

xerecept is not a potential treatment for cancer, but may reduce the edema associated with tumors and as a result, decrease neurological symptoms.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of a primary malignant glioma. * symptomatic peritumoral brain edema requiring initiation or increase of dexamethasone treatment. * if a patient is on dexamethasone for treatment of symptomatic peritumoral brain edema, the dose must be stable and should not exceed 24mg/dl for a minimum of 7 days prior to baseline. * presence of peritumoral brain edema confirmed by mri scan or comparable diagnostic technology obtained within 21 days of baseline. * capable of self-administration of subcutaneous injections twice daily for 8 weeks or availability of assistance from caregiver. exclusion criteria: * need for surgery, radiosurgery or radiation therapy or the introduction of new chemotherapeutic regime within 2 weeks of study treatment. * systemic steroid use for any other indication than peritumoral brain edema. * patients on dexamethasone or anticonvulsant therapy. * serious concomitant cardiovascular, pulmonary, renal, gastrointestinal or endocrine metabolic disease which could put the patient at unusual risk for study participation. * central nervous system (cns) infection. * conditions that are considered contradictions for patients to receive niacin

Keywords: peritumoral brain edema edema malignant brain tumor astrocytoma brain tumor dexamethasone decadron
therapeutic effects of video game play therapy on patients with chronic low back pain

Conditions: Chronic Low Back Pain

Summary: the purpose of this study is to investigate the video game play therapy in patients with chronic low back pain.

understanding the short- and medium-term therapeutic effects of video game play therapy for patients with chronic low back pain.

Eligibility criteria:
inclusion criteria: * chronic low back pain exclusion criteria: 1. low back pain accompanied by specific pathological conditions, such as infection, inflammation, fracture, or tumor 2. history of low back surgery with an implant 3. pregnancy of plans to become pregnant during the course of study 4. having received concurrent treatment for low back pain followed by another health care professional

Keywords: chronic low back pain video game therapeutic effects
an evaluation of the efficacy and safety of tegaserod 6 mg bid given orally to chinese patients with chronic constipation

Conditions: Constipation

Summary: tegaserod is an aminoguanidine indole compound and a member of a new class of 5-hydroxytryptamine (5-ht) agonists. activation of 5-ht4 receptors triggers the release of neurotransmitters from the enteric nerves which in turn stimulate contractility and peristalsis. this study will investigate the efficacy and safety of tegaserod against chronic constipation in a chinese population of adult men and women


Eligibility criteria:
inclusion criteria: * men or women at least 18 years of age * history of constipation for at least 6 months prior to screening * normal bowel evaluation performed within the past 5 years exclusion criteria: * most bothersome symptom in last 6 months is abdominal pain/discomfort * whose chronic constipation is thought to be a result of bowel surgery, gynecological surgery, neurologic disorder, systemic sclerosis, amyloidosis, scleroderma, myotonic dystrophy * insulin dependent diabetes * evidence of cathartic colon or laxative abuse other inclusion/exclusion criteria may apply.

Keywords: chronic constipation 5-ht,5-ht4, functional gi china tegaserod
the effect of compression stockings on the complaints of pregnant women with restless leg syndrome

Conditions: Restless Legs Syndrome; Pregnancy Related; Sleep Disorder

Summary: the aim of this project is to determine the effect of compression stockings on the complaints, well-being and sleep quality of pregnant women with restless legs syndrome (rls). the research is a pretest-posttest randomized placebo-controlled experimental study. the study will be carried out with a total of 70 people, 35 in the compression stocking group and 35 in the placebo stocking group. study data will be collected with rls diagnostic criteria questionnaire form, research criteria compliance form, personal information form, rls severity rating scale, pittsburgh sleep quality index (puki), who-5 and implementation satisfaction form. pregnant women in both groups will wear the stockings given for three weeks after the first interview. data analysis obtained in the research will be performed in turcosa statistical software (turcosa analytics ltd co, turkey, www.turcosa.com.tr).in comparisons, a value of p \<0.05 will be considered statistically significant. in order to conduct the study, the necessary academic committee decision, ethics committee approval (december 08, 2021 and number 2021/781) and institutional permission were obtained. the individuals included in the study will be informed about the purpose of the research, their verbal consent will be obtained and the participant's informed consent form will be signed.


Eligibility criteria:
inclusion criteria: 1. least literate, 2. between the ages of 18 and 40, 3. at 27 and above gestational week, 4. single pregnancy, 5. presence of rls according to the rls diagnostic criteria questionnaire form, 6. having a severity of 11 and above according to the rls severity rating scale, 7. using iron, vitamin d, magnesium and calcium, 8. pregnant women with a hemoglobin level of 11 g/dl and above, 9. pregnant women who can wear socks all day long, except for going to sleep, will be included in the study. exclusion criteria: 1. having a communication barrier, 2. having a risky pregnancy (risk of preterm labor, cervical insufficiency, preeclampsia, polyhydramnios, macrosomic baby, etc.), 3. having rls before pregnancy, 4. having a chronic disease (diabetes, hypertension, thyroid, cardiovascular disease, etc.), 5. with maternal obesity (bmi\>30) 6. having sleep apnea before pregnancy, 7. having any psychiatric disease and using antipsychotic and antidepressant drugs, 8. using heparin, antihistamine, antiemetic, calcium channel blocker, dextromethorphan and decongestant type drugs, 9. having a dermatological problem in the feet and legs, 10. pregnant women with varicose veins on their feet and legs will not be included in the study
emotional freedom technique (eft) on pain and stress levels in fibromyalgia (fms)

Conditions: Fibromyalgia

Summary: the main aim of the study was to investigate self-administered emotional to determine the effect of the freedom technique on pain and stress levels. the sub-objectives of the study are as follows: 1. to determine the effect of self-administration of eft on pain level. 2. to determine the effect of self-administered eft on stress level. 3. to determine the effect of eft self-administration on comfort level.

hypotheses of the research h 1 : between the pain levels of patients with and without self-administered eft there is a difference. h 2 : there is a difference between the stress levels of patients who apply eft to themselves and those who do not. there is a difference. h 3 : comfort levels of patients with and without self-administered eft there is a difference.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of fibromyalgia * can speak and understand turkish * have time and place orientation * no psychiatric illness, * no vision and hearing problems. exclusion criteria: * unstable medical condition * non-cooperative individuals

Keywords: fibromyalgia, emotional free technique pain stress comfort
genetic polymorphisms of tnf-α promoter and hbv genotype on outcome of hbv-related chronic liver disease

Conditions: Chronic Liver Disease; Hepatocellular Carcinoma

Summary: the prognosis of hepatitis b virus (hbv)infection varies from minimal progressive liver disease to cirrhosis or hepatocellular carcinoma (hcc).both viral and host genetic factors contribute to disease severity. cytokine gene polymorphism has been regarded affecting prognosis of disease. by detecting hbv genotyping and tumor necrosis factor-alpha polymorphism, this study aime to assess their effects and interaction on disease severity of hbv-related chronic liver disease and hcc.


Eligibility criteria:
inclusion criteria: * hbv-positive patients exclusion criteria: * hbv-negative patients
sub occipital inhibition technique on postural balance

Conditions: Movement Disorders

Summary: in the present study the investigators want to verify if the inhibition of the suboccipital muscles improves the postural balance in subjects with cervical pain objectified by stabilometry.


Eligibility criteria:
inclusion criteria: * individuals who suffer neck pain for at least 3 months * come to receive physiotherapy treatment at clinica osteomed (nrs: 8415-cv), elche, alicante, spain. * age between 18 and 65 years old. * sign the informed consent. exclusion criteria: * suffering or having suffered pathologies of the postural control system (postural sensors, central nervous system or locomotor system) * presenting deformities or orthopedic injuries in the lower limbs or rachis * presenting pain at the moment of study * present contraindications to the intervention under study * have received physiotherapy treatment in the last six months * have undergone surgical treatment of any kind.
impact of olfactory odour stimulation on energy expenditure

Conditions: Obesity

Summary: in this preliminary short-term study it is investigated, whether a short olfactory stimulation with distinct odours impacts energy expenditure in patients with obesity and lean patients.


Eligibility criteria:
inclusion criteria: * • age 18-55 years * obesity (bmi ≥30 kg/m2) and lean (bmi 18-25 kg/m2) * written informed consent * normosmia (defined by sniffing sticks test) exclusion criteria: * • chronic or acute sinusitis * surgical intervention of the nasal cavity or the paranasal sinus * known allergy to odors used in the study * smokers * current illicit drug abuse including daily marijuana and cannabidiol (cbd) consumption (alcohol ≤2 drinks per day allowed) * any kind of severe chronic disease (e.g. severe heart failure, active cancer disease) * diabetes mellitus * treatment with insulin sensitizing drugs including glucagon-like peptide (glp)-1 analogues within the last 3 months * history of neurodegenerative diseases, severe head trauma * severe renal impairment (e.g. estimated glomerular filtration rate \<30 ml/min/m2) * known liver cirrhosis or other severe liver impairment * use of any kind of decongestant more than twice a week * use of cortisone-containing nasal spray within the last 3 months * acute upper respiratory tract infection * uncontrolled dysthyroidism * uncontrolled hypertension * regular use of psychopharmaceutic drugs * study participants aims to start a new diet or exercise program during the study * bariatric surgery * pregnancy/lactation * onset of climacteric symptoms within one year (e.g. hot flashes and/or diaphoresis) or initiation of hormonal replacement therapy in the last three months * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. * participation in an interventional study within the last 3 months
preventing falls and participation restrictions in neurological diseases

Conditions: Multiple Sclerosis; Parkinson Disease; Stroke

Summary: a randomized open clinical trial to assess the added value of a comprehensive rehabilitation program on fall prevention and improve participation and activities of daily living. baseline assessment, 6-month experimental intervention (experimental group) vs. usual rehabilitation programs and assessment at end of treatment and six months after treatment will be performed.

90 patients will be randomly patients will be stratified by disease type and randomized separately. the trial will be organized in baseline assessment (clinical characteristics; fall predictors, chosen among the variables found to predict falls in the observational study), experimental intervention (experimental group) vs. usual rehabilitation programs (control group) and assessment at end of treatment and six months after treatment. the aim of the treatment will be the prevention of falls.

Eligibility criteria:
inclusion criteria: patients with stroke, parkinson's disease and multiple sclerosis residing in the centers' catchment areas, requiring rehabilitation, and releasing a written informed consent. exclusion criteria: 1. cognitive impairment (minimental state examination score \<21); 2. major depression; 3. severe joint/bone disorder interfering with mobility, 4. aphasia if interfering with understanding the aims of the study and self-administered tests; 5. relapses in the previous three months (ms); 6. stroke occurred in least four weeks before study entry.

Keywords: falls prevention education neurological disease